Volatility & Risk
Longevity Health has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500. Comparatively, Longevity Health’s rivals have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.
Valuation and Earnings
This table compares Longevity Health and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Longevity Health | $1.05 million | -$10.37 million | -0.08 |
| Longevity Health Competitors | $58.84 million | -$32.15 million | 4.18 |
Longevity Health’s rivals have higher revenue, but lower earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
Profitability
This table compares Longevity Health and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Longevity Health | -682.67% | N/A | -261.90% |
| Longevity Health Competitors | -672.41% | -133.75% | -59.01% |
Summary
Longevity Health rivals beat Longevity Health on 5 of the 9 factors compared.
About Longevity Health
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
Receive News & Ratings for Longevity Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Longevity Health and related companies with MarketBeat.com's FREE daily email newsletter.
